<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04689932</url>
  </required_header>
  <id_info>
    <org_study_id>RMFPC-ISS002</org_study_id>
    <nct_id>NCT04689932</nct_id>
  </id_info>
  <brief_title>Triferic AVNU Infusion Via Freedom Pump During Hemodialysis</brief_title>
  <official_title>Triferic AVNU Infusion Via Freedom Pump During Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockwell Medical Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rockwell Medical Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the delivery of Triferic AVNU intravenously&#xD;
      using the Freedom Pump-20 during hemodialysis into the pre-dialyzer and post-dialyzer blood&#xD;
      lines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, multi dose, open label study assessing the delivery of Triferic AVNU&#xD;
      administered intravenously to adult patients (&gt; or equal to 18 years of age) using the&#xD;
      Freedom Pump-20 during hemodialysis into the pre-dialyzer and post-dialyzer blood lines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Actual">June 19, 2021</completion_date>
  <primary_completion_date type="Actual">June 19, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time for complete infusion of 4.5 mL Triferic AVNU pre-Dialyzer</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time for complete infusion of 4.5 mL Triferic AVNU post-Dialyzer</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean TSAT Max pre-Dialyzer</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean TSAT Max post-Dialyzer</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Pre- Dialyzer Infusion and Post- Dialyzer Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On study day 1, day 3 and day 5, patients will receive 6.75 mg Fe/4.5 mL Triferic AVNU intravenously using the Freedom Pump-20 during hemodialysis into the pre-dialyzer blood line. On study day 2, day 4 and day 6, patients will receive the 6.75 mg Fe/4.5 mL Triferic AVNU intravenously using the Freedom Pump-20 during hemodialysis into the post dialysis blood line.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triferic AVNU</intervention_name>
    <description>Ferric Pyrophosphate Citrate</description>
    <arm_group_label>Pre- Dialyzer Infusion and Post- Dialyzer Infusion</arm_group_label>
    <other_name>FPC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant must be 18 years of age inclusive, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          2. Receiving chronic hemodialysis for 3-4 hours each session 3x/week.&#xD;
&#xD;
          3. Medically stable according to the investigator opinion&#xD;
&#xD;
          4. Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in this&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hemodynamically unstable during hemodialysis&#xD;
&#xD;
          2. Evidence of active bleeding from the GI tract.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond D Pratt, MD, FACP</last_name>
    <role>Study Director</role>
    <affiliation>Rockwell Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Luxury Dialysis</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

